Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening
International Journal of Molecular Sciences · 07.01.2025 · 26 (2) · 437
DOI: 10.3390/ijms26020437 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.01.2025. Verfasst von Anna Demchenko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia. Hauptthemen laut MEDLINE: Organoids, Cystic Fibrosis, Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation for RCMG.
Abstract (Originalsprache)
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CFTR gene. Currently, CFTR modulators are the most effective treatment for CF; however, they may not be suitable for all patients. A representative and convenient in vitro model is needed to screen therapeutic agents under development. This study, on the most common mutation, F508del, investigates the efficacy of human induced pluripotent stem cell-derived lung organoids (hiLOs) from NKX2.1+ lung progenitors and airway basal cells (hiBCs) as a 3D model for CFTR modulator response assessment by a forskolin-induced swelling assay. Weak swelling was observed for hiLOs from NKX2.1+ lung progenitors and hiBCs in response to modulators VX-770/VX-809 and VX-770/VX-661, whereas the VX-770/VX-661/VX-445 combination resulted in the highest swelling response, indicating superior CFTR function restoration. The ROC analysis of the FIS assay results revealed an optimal cutoff of 1.21, with 65.9% sensitivity and 71.8% specificity, and the predictive accuracy of the model was 76.4%. In addition, this study compared the response of hiLOs with the clinical response of patients to therapy and showed similar drug response dynamics. Thus, hiLOs can effectively model the CF pathology and predict patients’ specific response to modulators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia.
- Scientific and Educational Resource Center, Peoples' Friendship University of Russia, Miklukho-Maklaya, 6, 117198 Moscow, Russia.
- Department of Cell Technology, Endocrinology Research Center, Dm. Ulyanova Str., 11, 117292 Moscow, Russia.
- Moscow Branch of the Biobank "All-Russian Collection of Biological Samples of Hereditary Diseases", Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia.
- DNA-Diagnostics Laboratory, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia.
- Laboratory of Cystic Fibrosis, Research Institute of Pulmonology, 11th Parkovaya Str., 32/4, 105077 Moscow, Russia.
ORCID-Profile: Maxim Balyasin, Olga Schagina, Elena Amelina
Förderung
- Ministry of Science and Higher Education of the Russian Federation for RCMG
Zitieren
APA
Demchenko, A., Balyasin, M., Nazarova, A., Grigorieva, O., Panchuk, I., Kondrateva, E., Tabakov, V., Schagina, O., Amelina, E., & Smirnikhina, S. (2025). Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening. International Journal of Molecular Sciences, 26(2), 437. https://doi.org/10.3390/ijms26020437
Vancouver
Demchenko A, Balyasin M, Nazarova A, Grigorieva O, Panchuk I, Kondrateva E, et al. Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening. International Journal of Molecular Sciences. 2025;26(2):437. doi:10.3390/ijms26020437
BibTeX
@article{Demchenko2025,
author = {Demchenko, Anna and Balyasin, Maxim and Nazarova, Aleksandra and Grigorieva, Olga and Panchuk, Irina and Kondrateva, Ekaterina and Tabakov, Vyacheslav and Schagina, Olga and Amelina, Elena and Smirnikhina, Svetlana},
title = {Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {2},
pages = {437},
doi = {10.3390/ijms26020437}
}
EUVIMED